Joint Formulary & PAD

Lumacaftor with ivacaftor - Cystic fibrosis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Not Specified
Associated Icons :
BNF SPC
NHSE
Restrictions / Comments :

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Lumacaftor with ivacaftor
Indication :
Cystic fibrosis
Group Name :
Keywords :
Brand Names Include :
Orkambi
Important Information :
NHSE Specialist Commissioned Services only
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Lumacaftor with ivacaftor is used to treat.

  • No records returned.

Committee Recommendations (1)

16 Apr 18 - Not Set
This drug / device falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.
Treatment should remain with the specialist (RED) hospital only drug.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.